B. Metzler seel. Sohn & Co. AG Makes New $1.40 Million Investment in AtriCure, Inc. $ATRC

B. Metzler seel. Sohn & Co. AG bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 49,876 shares of the medical device company's stock, valued at approximately $1,396,000. B. Metzler seel. Sohn & Co. AG owned 0.10% of AtriCure at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new position in AtriCure in the 2nd quarter valued at $37,000. Harbor Investment Advisory LLC acquired a new stake in AtriCure during the second quarter worth about $40,000. Smartleaf Asset Management LLC increased its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after buying an additional 429 shares during the period. Fifth Third Bancorp bought a new position in AtriCure in the 1st quarter valued at about $51,000. Finally, Global Retirement Partners LLC acquired a new position in shares of AtriCure in the 2nd quarter valued at approximately $52,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $48.98 on Monday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm has a market cap of $2.49 billion, a PE ratio of 233.25 and a beta of 1.20. The company's fifty day simple moving average is $35.83 and its 200 day simple moving average is $31.81. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $49.20.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on ATRC shares. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday. Zacks Research upgraded AtriCure from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 24th. UBS Group lowered their target price on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday, July 21st. Finally, Citigroup reissued a "market outperform" rating on shares of AtriCure in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and an average target price of $48.50.

Insiders Place Their Bets

In other news, Director Karen Prange sold 3,564 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares of the company's stock, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is currently owned by corporate insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source